Skip to Main Content

Paper Details

Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer.
Clin Cancer Res
25
2021
BRCA1, HER2, HR, HR+/HER2- tumors, KMTD2, MYB, MYC, Metastatic Breast Cancer, PIK3CA, SETD2, TMB, TP53, breast cancer, copy-number variations, dnMBC, metastatic breast cancer, metastatic tumors, patients, primary, primary tumors, rMBC, stage I-III, triple-negative, triple-negative dnMBC, tumors
Author NameAffiliation
Ana C Garrido-CastroDana-Farber Cancer Institute
Ana C Garrido-CastroHarvard Medical School
Andrew D CherniackDana-Farber Cancer Institute
Andrew D CherniackBroad Institute of MIT and Harvard
Andrew D CherniackHarvard Medical School
Andrew D CherniackDana-Farber Cancer Institute
Andrew D CherniackHarvard Medical School
Andrew D CherniackBroad Institute of MIT and Harvard
Ethan CeramiDana-Farber Cancer Institute
Ethan CeramiDana-Farber Cancer Institute
Laura E MacConaillHarvard Medical School
Laura E MacConaillCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute
Laura E MacConaillBrigham and Women' Hospital
Ian E KropDana-Farber Cancer Institute
Ian E KropHarvard Medical School
Nikhil WagleDana-Farber Cancer Institute
Nikhil WagleBroad Institute of MIT and Harvard
Nikhil WagleHarvard Medical School
Nikhil WagleDana-Farber Cancer Institute
Nikhil WagleHarvard Medical School
Nikhil WagleBroad Institute of MIT and Harvard
Eric P WinerDana-Farber Cancer Institute
Eric P WinerHarvard Medical School
Nancy U LinDana-Farber Cancer Institute
Nancy U LinHarvard Medical School
  • 1 - 25

Datasets

Release 1.2